Elos Medtech achieves a milestone within Dental Implant Systems
Elos Medtech announces that the company has received FDA 510(k) clearance to market Elos Abutment Blanks on the US dental implant market. The Elos Abutment Blank is now a 510(k) cleared class II device to be used for milling of customized abutments for the restoration of single dental implants.
The North American market is of significant importance and is estimated to constitute approximately 35% of the total global dental implant market. The segment of milled customized prosthetics is growing compared to the conventional casting technique and therefore the function of abutment blanks fills a valued position within the evolving needs of digital dentistry. The Elos Abutment Blank is compatible with multiple implant platforms and will primarily be marketed to milling centres and dental laboratories offering modern and efficient prosthetic solutions for their customers.
“It is with great pleasure that we announce our first 510(k) cleared dental product, the Elos Abutment Blank, for the US market. It is an important milestone for Elos Medtech as we take our next strategic steps to embrace the US market“, says Søren Olesen, Managing Director of Elos Medtech Pinol and Dental Business Director. “This is a confirmation of our dental commitment and will serve as a solid platform for the growth of our dental offering in the US.”
Thanks to the accuracy and flexibility of the Elos Accurate® dental product portfolio, Elos Medtech has achieved a leadership and premium position on the digital dentistry market. Elos Accurate® enables an open digital workflow which is recognized by a growing number of customers worldwide.
Elos Medtech is one of the leading development and production partners for medical technology products and components in the world, such as dental and orthopedic implants and instruments. The operations are conducted at facilities in Sweden, Denmark, China and the US. Customers are internationally active medical technology companies.
Elos Medtech employs more than 500 people worldwide and generates revenue that exceeds MSEK 550. Elos Medtech has been traded on NASDAQ Stockholm AB since 1989. The Elos Medtech B share is classified as a Health Care company on the Small Cap list.
Gothenburg, February 23, 2018
Elos Medtech AB (publ)
For further information, please contact: Jan Wahlström, CEO, +46 70 212 18 89, firstname.lastname@example.org Søren Olesen, Managing Director Elos Medtech Pinol, Dental Business Director, +45 40 41 28 82, email@example.com
For additional information about the Elos Medtech Group, visit www.elosmedtech.com